Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Susanne Strifler"'
Autor:
Anke Schilhabel, Mouhamad Khouja, Peter Stewart, Susanne Strifler, Thomas Stuebig, Miriam Kull, Claudia Baldus, Christiane Pott, David Gonzalez de Castro, Monika Engelhardt, Jan Krönke, Hermann Einsele, Stefan Knop, Monika Brüggemann
Publikováno v:
HemaSphere, Vol 7, p e077086d (2023)
Externí odkaz:
https://doaj.org/article/c3b0f22dd6eb4bac9e1e3af23bfdd629
Autor:
Sophia Danhof, Martin Schreder, Stefan Knop, Leo Rasche, Susanne Strifler, Claudia Löffler, Tea Gogishvili, Hermann Einsele, Michael Hudecek
Publikováno v:
Haematologica, Vol 103, Iss 3 (2018)
Externí odkaz:
https://doaj.org/article/40305e8c9d0244548239a44a1e7b0d15
Publikováno v:
Case Reports in Oncology, Vol 8, Iss 1, Pp 189-195 (2015)
Background: Therapy for multiple myeloma (MM) has substantially improved in the era of immunomodulatory drugs and bortezomib. However, the prognosis of patients with progressive disease despite treatment with these ‘novel agents' remains poor. Rece
Externí odkaz:
https://doaj.org/article/0cc1503cde6b458a986a28d87905084e
Autor:
Max Bittrich, Martin Schreder, Sophia Danhof, Hermann Einsele, Jochen Hefner, Heinz Gisslinger, Stefan Knop, Dorothea Hose, Susanne Strifler, Renate Schoder, Bettina Gisslinger, Maria-Theresa Krauth
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Background The anti-SLAMF7 monoclonal antibody, elotuzumab (elo), plus lenalidomide (len) and dexamethasone (dex) is approved for relapsed/refractory MM in the U.S. and Europe. Recently, a small phase 2 study demonstrated an advantage in progression-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1cadf75924d21385625334cdb6e5bbc
https://doi.org/10.1007/s00432-020-03323-6
https://doi.org/10.1007/s00432-020-03323-6
Autor:
Joaquin Martinez-Lopez, Susanne Strifler, Larissa Haertle, K. Martin Kortüm, Ralf C. Bargou, Markus Roth, Andoni Garitano-Trojaola, Maximilian Johannes Steinhardt, Umair Munawar, Panagiota Arampatzi, Matteo DaVia, Tobias Heckel, Hermann Einsele, Nicole Müller, Thorsten Stühmer, Cornelia Vogt, Sascha Dietrich, Leo Rasche, Miguel Gallardo, Santiago Barrio
Publikováno v:
Blood. 134:836-840
TO THE EDITOR: Recently, biallelic (“double hit”) TP53 inactivation, occurring in 2% to 4% of newly diagnosed multiple myeloma (MM) patients, was identified as an ultimate high-risk feature of MM, being associated with median survival of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24bec71ebae128b9b4055bdfa1dd43af
https://doi.org/10.1182/blood.2019000080
https://doi.org/10.1182/blood.2019000080
Autor:
Martin Schreder, Michael Hudecek, Xiang Zhou, Anja Mottok, Elena Gerhard-Hartmann, Andreas Rosenwald, Teresa Kilian, Sophia Danhof, Hermann Einsele, Tabea Steinmüller, Susanne Strifler, Leo Rasche
Publikováno v:
Annals of Hematology
Extramedullary disease (EMD) represents a high-risk state of multiple myeloma (MM) associated with poor prognosis. While most anti-myeloma therapeutics demonstrate limited efficacy in this setting, some studies exploring the utility of chimeric antig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4a9e9fb87d72bd1c62c8824f5362765
https://opus.bibliothek.uni-wuerzburg.de/files/26646/Danhof_Annals.pdf
https://opus.bibliothek.uni-wuerzburg.de/files/26646/Danhof_Annals.pdf
Autor:
Erdwine Klinker, Tobias Gassenmaier, Sven Schimanski, Sebastian Knorz, Petra Schulze, Benedikt Weissbrich, Susanne Strifler, Hartwig Klinker, Susanne Wiebecke
Publikováno v:
Archives of Clinical and Medical Case Reports.
Introduction: Patients with haematological malignancies after chemotherapy are immunocompromised and therefore highly susceptible to Covid-19 disease. Case presentation: The case report presents a patient with mantel cell lymphoma who experienced a s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75a91d4fb9d9553f9527835225491715
https://doi.org/10.26502/acmcr.96550397
https://doi.org/10.26502/acmcr.96550397
Autor:
Stefan Knop, Susanne Strifler
Publikováno v:
Future Oncology. 14:3123-3134
Despite improvement of prognosis since approval of proteasome inhibitors and immunomodulatory drugs, myeloma remains largely incurable. The outcome of first-line treatment is known to be crucial for survival and, therefore, implementation of novel st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd25fa97506388723403b7f961ce8615
https://doi.org/10.2217/fon-2018-0040
https://doi.org/10.2217/fon-2018-0040
Autor:
Eva Teufel, Andreas Beilhack, Larissa Haertle, K. Martin Kortüm, Constantin Lapa, Nadine Rhodes, Antonio Giovanni Solimando, Umair Munawar, Cornelia Vogt, Matteo Claudio Da Via, Hermann Einsele, Santiago Barrio, Leo Rasche, Andoni Garitano-Trojaola, Susanne Strifler
Combined MEK-BRAF inhibition is a well-established treatment strategy in BRAF-mutated cancer, most prominently in malignant melanoma with durable responses being achieved through this targeted therapy. However, a subset of patients face primary unres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::019c0479943c71c903091adbd65a9694
https://europepmc.org/articles/PMC7011664/
https://europepmc.org/articles/PMC7011664/
Autor:
Umair, Munawar, Leo, Rasche, Nicole, Müller, Cornelia, Vogt, Matteo, Da-Via, Larissa, Haertle, Panagiota, Arampatzi, Sascha, Dietrich, Markus, Roth, Andoni, Garitano-Trojaola, Maximilian Johannes, Steinhardt, Susanne, Strifler, Miguel, Gallardo, Joaquin, Martinez-Lopez, Ralf C, Bargou, Tobias, Heckel, Hermann, Einsele, Thorsten, Stühmer, K Martin, Kortüm, Santiago, Barrio
Publikováno v:
Blood. 134(10)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8fa22b42088842f041b0b7613dcd6d86
https://pubmed.ncbi.nlm.nih.gov/31340981
https://pubmed.ncbi.nlm.nih.gov/31340981